Ultrashort DAPT Cuts Bleeding in ACS Without Raising Overall Ischemia
This meta-analysis clarifies that the safety of ultrashort dual antiplatelet therapy in acute coronary syndrome hinges on preserving potent P2Y12 inhibitor monotherapy and on ACS subtype, informing de-escalation decisions at the bench.
Ultrashort DAPT reduces bleeding without raising overall ischemic events in PCI-treated ACS patients.
Balancing efficacy and bleeding risk in dual antiplatelet therapy (DAPT) is crucial for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Ultrashort DAPT reduced major bleeding (HR: 0.47) without increasing major adverse cardiac and cerebrovascular events (MACCE) risk overall, but MACCE risk increased in STEMI cases. The study supports using ultrashort DAPT followed by monotherapy in ACS patients post-PCI for reduced bleeding, with careful consideration for STEMI and ethnicity impacts. Ultrashort DAPT may benefit ACS patients needing PCI by lowering bleeding risk without overall MACCE increase.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.